NVCT — Nuvectis Pharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1875558 ·
Last close
$19.20
Market Cap
$660.27M
52W High
$29.27
52W Low
$5.77
ADV30
198,530
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -31,049,000 | -30,070,000 | 140,839,000 | 140,707,000 | 14,193,000 |
| Jun 2026 | 0 | — | -7,197,000 | -7,020,000 | 22,376,000 | 22,160,000 | 13,294,000 |
| Mar 2026 | 0 | — | -6,260,000 | -6,050,000 | 25,398,000 | 25,130,000 | 11,178,000 |
| Dec 2025 | 0 | — | -7,617,000 | -7,314,000 | 31,709,000 | 31,634,000 | 13,296,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-40,294,000
Investing CF
$0
Financing CF
$145,559,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.02
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-142,827,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-52,123,000
Pretax Income TTM
$-50,454,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -27,574,000 | -26,442,000 | 31,709,000 | 13,296,000 | 18,413,000 | -16,009,000 |
| Dec 2024 | 0 | -19,847,000 | -19,000,000 | 18,607,000 | 8,894,000 | 9,713,000 | -12,247,000 |
| Dec 2023 | 0 | -22,897,000 | -22,260,000 | 19,185,000 | 6,984,000 | 12,201,000 | -15,954,000 |
| Dec 2022 | 0 | -19,234,000 | -19,085,000 | 20,405,000 | 6,186,000 | 14,219,000 | -13,559,000 |
TTM Snapshot
Revenues TTM
$6,514,000
NetIncome TTM
$-27,846,000
OpCashFlow TTM
—
Assets (Latest)
$22,376,000
Forward EPS
$-0.96
Max Pain — expiry 2027-01-15
max pain strike: $15.00 · spot: $20.29 · call oi: 1,464 · put oi: 19
Expected Move to 2027-01-15:
±$5.53
(27.23%) —
implied range
$14.76 –
$25.81
· ATM straddle on $20.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANNX | Annexon, Inc. | $661.95M | $3.47 | — |
| JANX | Janux Therapeutics, Inc. | $655.27M | $10.71 | — |
| GERN | GERON CORP | $644.24M | $1.00 | — |
| SVA | SINOVAC BIOTECH LTD | $642.44M | $6.47 | — |
| BCAX | Bicara Therapeutics Inc. | $637.32M | $9.60 | — |
News headlines (Yahoo Finance, 1h cache)
Nuvectis Pharma, Inc. Q3 2026 Earnings Call Summary
2026-11-04 23:24 · Yahoo
Nuvectis Pharma Inc (NVCT) (Q3 2026) Earnings Call Highlights: Late-Stage Transformation, $140 ...
2026-11-04 21:06 · Yahoo
Nuvectis (NVCT) Q3 2026 Earnings Call Transcript
2026-11-04 17:17 · Yahoo
Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
2026-11-04 12:00 · Yahoo
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
2026-11-02 22:00 · Yahoo
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
2026-10-26 12:30 · Yahoo
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
2026-10-09 12:00 · Yahoo
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
2026-09-24 12:00 · Yahoo
Nuvectis Pharma To Participate in Upcoming Investor Conferences
2026-09-03 12:00 · Yahoo
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
2026-08-19 15:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.